Sugi Predict

Sugi Predict / Compounds / SCHEMBL20595486

SCHEMBL20595486

SCHEMBL20595486

c1ccc(COc2ccc(OC3CCN(c4ccccc4)CC3)c(OCc3ccccc3)n2)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HTR2C P28335 1/20 0.42
▸ HTR2B P41595 1/20 0.42
▸ HRH4 Q9H3N8 2/20 0.39
▸ CYP11B2 P19099 1/20 0.39
▸ SLC6A4 P31645 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ DNMT3A Q9Y6K1 1/20 0.37
▸ FFAR4 Q5NUL3 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ ACACB O00763 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ HRH3 Q9Y5N1 1/20 0.36
▸ F10 P00742 1/20 0.36
▸ ENPP2 Q13822 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31108082 1.00 HTR2C (0.42) HTR2CHTR2BHRH4CYP11B2SLC6A4
SCHEMBL26329075 0.79 HDAC8 (0.43) —
SCHEMBL21903078 0.79 HDAC8 (0.43) —
SCHEMBL21965434 0.77 SLC6A4 (0.41) HTR2CHTR2BSLC6A4L3MBTL1
SCHEMBL7961307 0.75 F10 (0.52) HTR2CHTR2BHRH3F10
SCHEMBL31692672 0.74 NPC1 (0.42) HRH4CYP11B2ALDH1A1ALOX15TSHR
SCHEMBL23983456 0.74 MAPT (0.38) HRH4CYP11B2ALDH1A1SMN1; SMN2HRH3
SCHEMBL29681555 0.74 MAPT (0.38) HRH4CYP11B2ALDH1A1SMN1; SMN2HRH3
SCHEMBL23983537 0.73 LRRK2 (0.44) HRH4CYP11B2ALDH1A1ALOX15TSHR
SCHEMBL31692696 0.73 NT5E (0.40) HRH4ACACBENPP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4717317-A2 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION C4 Therapeutics, Inc. (US) 2026-04-01 — — EP disclosed
EP-3641762-B1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION C4 THERAPEUTICS INC (US) 2026-02-18 — — EP disclosed
US-20260015362-A1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2026-01-15 — — US disclosed
US-12441740-B2 N/O-linked degrons and degronimers for protein degradation C4 THERAPEUTICS, INC. (US) 2025-10-14 — — US disclosed
US-20250101037-A1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2025-03-27 — — US disclosed
US-12180225-B2 N/O-linked degrons and degronimers for protein degradation C4 THERAPEUTICS, INC. (US) 2024-12-31 — — US disclosed
US-20230279023-A1 N/O-Linked Degrons and Degronimers for Protein Degradation C4 THERAPEUTICS, INC. (US) 2023-09-07 — — US disclosed
US-20230279023-A1 N/O-Linked Degrons and Degronimers for Protein Degradation C4 THERAPEUTICS, INC. (US) 2023-09-07 — — US disclosed
US-20230279023-A1 N/O-Linked Degrons and Degronimers for Protein Degradation C4 THERAPEUTICS, INC. (US) 2023-09-07 — — US disclosed
US-11459335-B2 N/O-linked Degrons and Degronimers for protein degradation C4 THERAPEUTICS, INC. (US) 2022-10-04 — — US disclosed
US-20200140456-A1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2020-05-07 — — US disclosed
US-20200140456-A1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2020-05-07 — — US disclosed
EP-3641762-A1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION C4 Therapeutics, Inc. (US) 2020-04-29 — — EP disclosed
CN-110769822-A N/O-linked degron and degron bodies for protein degradation C4医药公司 2020-02-07 — — CN disclosed
WO-2018237026-A1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION C4 THERAPEUTICS, INC. (US) 2018-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12441740-B2 N/O-linked degrons and degronimers for protein degradation CRBN, CBL, STUB1 HTR2C 3436/4885HTR2B 3987/4885HRH4 4498/4885
US-20250101037-A1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION CRBN, CBL, STUB1 HTR2C 3436/4885HTR2B 3987/4885HRH4 4498/4885
US-12180225-B2 N/O-linked degrons and degronimers for protein degradation CRBN, CBL, STUB1 HTR2C 3436/4885HTR2B 3987/4885HRH4 4498/4885
US-20260015362-A1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION CRBN, CBLC, CBL HTR2C 956/4885HTR2B 3263/4885HRH4 2383/4885
US-20230279023-A1 N/O-Linked Degrons and Degronimers for Protein Degradation CRBN, CBL, STUB1 HTR2C 3436/4885HTR2B 3987/4885HRH4 4498/4885
US-11459335-B2 N/O-linked Degrons and Degronimers for protein degradation CRBN, CBL, STUB1 HTR2C 3436/4885HTR2B 3987/4885HRH4 4498/4885
US-20200140456-A1 N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION CRBN, CBL, STUB1 HTR2C 3436/4885HTR2B 3987/4885HRH4 4498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.